The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study

Table 3 A full factorial model of ANCOVA to adjust the possible effect of anti-diabetic and anti-hypertensive drugs on circulating levels of CTRP5 in controls, NAFLD, T2DM and NAFLD + T2DM patients

Status	Status	Mean difference (I − J) ± SEM	p value	95 % confidence interval for difference
Status	Status	Mean difference (I − J) ± SEM	p value	Lower bound	Upper bound
Control	NAFLD	40.208 ± 3.164	0.000	31.657	48.759
	T2DM	45.197 ± 3.338	0.000	36.176	54.219
	NAFLD + T2DM	42.926 ± 3.293	0.000	34.028	51.824

NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, CTRP5 complement-C1q TNF-related protein 5, SEM standard error of mean

ISSN: 1758-5996